Name: Recombinant Human SUMO-conjugating enzyme UBC9 (UBE2I), partial
Brand: CUSABIO
SKU: CSB-EP025457HU1

Product Details

Purity

Greater than 90% as determined by SDS-PAGE.

Target Names

UBE2I

Uniprot No.

P63279

Research Area

Cell Cycle

Alternative Names

C358B7.1; p18; SUMO 1 protein ligase; SUMO conjugating enzyme UBC9; SUMO-conjugating enzyme UBC9; SUMO-protein ligase; SUMO1 protein ligase; UBC9; UBC9_HUMAN; UBCE9; Ube2i; Ubiquitin carrier protein 9; Ubiquitin carrier protein; Ubiquitin carrier protein I; Ubiquitin conjugating enzyme 9; Ubiquitin conjugating enzyme E2I (homologous to yeast UBC9); Ubiquitin conjugating enzyme E2I (UBC9 homolog; yeast); Ubiquitin conjugating enzyme UbcE2A; Ubiquitin like protein SUMO 1 conjugating enzyme; Ubiquitin protein ligase E2I; Ubiquitin-conjugating enzyme E2 I; Ubiquitin-protein ligase I

Species

Homo sapiens (Human)

Source

E.coli

Expression Region

1-157aa

Target Protein Sequence

MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGKKGTPWEGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAP
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.

Mol. Weight

44.9kDa

Protein Length

Partial

Tag Info

N-terminal GST-tagged

Form

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

CUSABIO synthesized the recombinant gene by integrating the N-terminal GST tag sequence into the targeted gene encoding the 1-157aa of the human UBE2I. The synthesized gene was subsequently cloned into an expression vector. After cloning, the expression vector was introduced into the E.coli for expression. The product was purified to obtain the recombinant human UBE2I protein carrying N-terminal GST tag. The SDS-PAGE assayed the purity of this recombinant UBE2I protein greater than 90%. This UBE2I protein migrated along the gel to a band of about 45 kDa molecular weight.

UBE2I is a gene providing instruction of making a protein named SUMO-conjugating enzyme UBC9 (also called Ubiquitin-protein ligase I and abbreviated as p18) in human and belongs to Ubiquitin-conjugating enzyme family. SUMO is an abbreviated form of small ubiquitin-like modifiers. SUMOylation is a process of covalent and reversible attaching of SUMO moiety to a target protein and is an important post-translational modification involved in various cellular processes. UBC9 is the unique SUMO E2 enzyme known ro conjugate SUMO to target substrates. The UBC9 serves as a lynchpin in the SUMO conjugateion pathway, interecting with the SUMO E1 during activation.

Target Background

Function

Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Mediates sumoylation of ERCC6 which is essential for its transcription-coupled nucleotide excision repair activity.

Gene References into Functions

Study demonstrated overexpression of Ubc9 protein in osteosarcoma. Silencing Ubc9 in osteosarcoma cell lines induced decoupling of SUMO1 from Cx43, generating increased free Cx43 levels, which is important for reconstructing gap junction intercellular communication and recovering cellular functions. PMID: 29956745
Data show that the forkhead Box Protein P3 (FOXP3) response element at the -310 bp region, but not the -2182 bp region, is mainly required for ubiquitin conjugating enzyme 9 (UBC9) activation by FOXP3. PMID: 30011797
Study provides an insight into the role of the RNF4 to balance the role of SUMO signaling by directly targeting Ubc9 and SUMO E3 ligases. PMID: 29180619
The SUMO1/UBC9 axis may regulate Nox1mediated diabetic retinopathy by inhibiting reactive oxygen species generation and apoptosis. PMID: 29138839
our results indicate that down-regulation of UBC9 sensitizes cells to anticancer drugs, is possibly associated with the regulation of ERK1/2 and P38 activation and interacts with the intrinsic apoptosis pathway. PMID: 28572537
Ubc9 is an essential regulator of ADAP where it is required for TCR-induced membrane recruitment of the small GTPase Rap1 and its effector protein RapL and for activation of the small GTPase Rac1 in T cell adhesion. PMID: 29127148
NUSAP1 contributes to accurate chromosome segregation by acting as a co-factor for RanBP2-RanGAP1-UBC9 during cell division. PMID: 28900032
Listeriolysin O -induced down-regulation of Ubc9 is independent of Ubc9-SUMO interaction, however, it may involve phosphorylation signaling. PMID: 28911869
Sumoylation of PML with SUMO2 by UBC9/UBE2I can lead to formation of polymeric SUMO chains. Data suggest that coordination of growing poly-SUMO chain with "back side" binding site on UBC9/UBE2I appears to be required for SUMO chain elongation on PML. (PML = promyelocytic leukemia protein; SUMO2 = small ubiquitin-like modifier 2; UBC9/UBE2I = ubiquitin-conjugating enzyme UBC9/UBE2I) PMID: 28784659
The role of Transthyretin in the regulation of Ubc9 SUMOylation PMID: 27501389
These findings point to UBC9 and autophagy as novel hallmarks of human papillomavirus oncogenesis PMID: 28253371
These findings reveal that SUMO E1~E2 oxidation is an essential redox switch in oxidative stress. PMID: 27174643
the mRNA and protein expression of Ubc9 are regulated by the microRNA miRNA-30a (miR-30a) in human subcutaneous adipocytes. PMID: 27758866
miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs. More specifically, it was demonstrated that miR-30e exhibited these effects on VSMCs partially through targeting Ube2i and downregulating the IkappaBalpha/NFkappaB signaling pathway. PMID: 28123167
Ubc9 plays different roles of action in antitumor agents in chemotherapy. The process requires bleomycin hydrolase and poly(ADP-ribose) polymerase-1. The results are beneficial to deeply understanding of Ubc9 functions and for precise prediction of chemotherapy outcomes in tumors. PMID: 27878232
Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. PMID: 27030546
Akt directly phosphorylates Ubc9 at Thr35 and phosphorylates SUMO1 at Thr76. Ubc9 phosphorylation at Thr35 promotes Ubc9 thioester bond formation and SUMO1 phosphorylation at Thr76 stabilizes the SUMO1 protein. PMID: 25867063
Characterization and Structural Insights into Selective E1-E2 Interactions in the Human and Plasmodium falciparum SUMO Conjugation Systems. PMID: 26697886
a high-throughput microscopy screen identified ubiquitin carrier protein 9 (Ubc9) as a negative regulator of energy storage in human sc adipocytes. Ubc9 depletion enhanced energy storage and induced the brown fat gene program in human sc adipocytes. PMID: 26192107
The authors show that ZNF451 is SUMO2 specific and that SUMO modification of ZNF451 may contribute to activity by providing a second molecule of SUMO that interacts with E2. PMID: 26524494
The RWD domain binds to a Ubc9 surface that also must interact with E1, E3, and SUMO. PMID: 25918163
These data show that NS5A is a target protein of small ubiquitin-like modifier (SUMO) and is SUMOylated at lysine residue 348 and silencing of UBC9 impaired hepatitis C virus replication. PMID: 24602294
SUMO E2 ligase Ubc9 has a critical role in oncogenesis driven by the Ras/Raf pathway PMID: 25805818
Ubc9 gene plays an important role in cell proliferation in epithelial ovarian cancer through PI3K/Akt signaling pathway. PMID: 23708104
Data indicate that protein tyrosine phosphatase 1B (PTP1B) association with calnexin is ubiquitin conjugating enzyme 9 (UBC9)-dependent. PMID: 25586181
N-terminal amino acid residues of Ubc9 are critical for Ubc9 nuclear enrichment and localization. PMID: 25637535
the Ran system and Ubc9 are functionally coupled to the structure of the nuclear lamina and reactive oxygen species production through feedback loops PMID: 24523287
Although E2 approximately SUMO-1 exhibits no specificity for product-bound TDG, the relatively high conjugation efficiency raises the possibility that E2-mediated sumoylation could stimulate product release in vivo. PMID: 24753249
The variability of the UBC9 gene can play a role in breast cancer occurrence. PMID: 23873416
UBC9 appears to play an important role in the tumor biology of Nigerian women. PMID: 24176171
miR-214 and its target gene UBC9 may contribute to the development and the clinical outcome of glioma PMID: 24277415
The proximal UBC9 promoter. PMID: 24086615
Study showed that ZHX1 is SUMOylated by Ubc9 with SUMO1 at the sites K159, K454, and K626 and that the SUMOylation of ZHX1 regulated the stability, ubiquitination and transcriptional activity of ZHX1. PMID: 23686912
This study provides further insight in the processing and packaging of the HIV-1 gp120 into mature HIV-1 virions. PMID: 23861967
We observed steady-state expression of SUMO-conjugated enzyme-UBC9 throughout normal gestation. Placental UBC9 levels were strikingly increased in severe pre-eclampsia patients. PMID: 23628505
These results suggest that the SUMOylation of DDB2 facilitates CPD repair. PMID: 23860269
we demonstrated that upregulation of Ubc9 expression promotes migration and invasion. Ubc9 likely plays an important role in cancer progression by promoting invasion and metastasis in lung cancer. PMID: 23381475
High UBC9 expression is associated with glioma. PMID: 23187003
From these observations, we concluded that UBC9 is a novel regulator of the mammalian ER stress response. PMID: 23470653
The E2 enzyme Ubc9 is an interaction partner of E1B-55K, providing a possible molecular explanation for SUMO-dependent modulation of cellular target proteins. PMID: 22614022
A previously undescribed SIRT1/Ubc9 regulatory axis in the modulation of protein sumoylation and the hypoxia response. PMID: 23395904
High Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis in breast cancer. PMID: 21880185
Data show that the SAE2 subunit of the small ubiquitin-like modifier (SUMO) E1 is autoSUMOylated at residue Lys-236, and SUMOylation was catalyzed by Ubc9 at several additional Lys residues surrounding the catalytic Cys-173 of SAE2. PMID: 22403398
UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PMID: 22114711
There was no statistical association of UBE2I expression between human epithelial ovarian cancer tumor and normal tissues PMID: 21971700
Ubc9 and PIAS1 potentiated SF-1-mediated transactivation of human CYP17, CYP11A1, and CYP11B1 but not CYP11B2 promoters. PMID: 21467194
Binding of BRCA1 proteins to nuclear chaperone Ubc9 provides a novel mechanism for nuclear import and control of tumor growth. PMID: 21344391
The authors propose that LMP1, by interaction with Ubc9, modulates sumoylation processes, which regulate signal transduction pathways that affect phenotypic changes associated with oncogenesis. PMID: 21795333
The authors report that the high risk human papillomavirus E6 proteins reduce the intracellular quantity of the sole SUMO conjugation enzyme, Ubc9, concomitant with decreased host sumoylation. PMID: 21510985
Analysis of the dynamics of E2(Ubc9)-SUMO-Target(RanGAP1) in the absence and presence of E3(RanBP2) revealed that two different allosteric sites regulate the ligase activity. PMID: 21216249

Hide All

Subcellular Location

Nucleus. Cytoplasm.

Protein Families

Ubiquitin-conjugating enzyme family

Tissue Specificity

Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus.

Database Links

HGNC: 12485

OMIM: 601661

KEGG: hsa:7329

STRING: 9606.ENSP00000324897

UniGene: Hs.302903

Code	CSB-EP025457HU1
Abbreviation	Recombinant Human UBE2I protein, partial
MSDS	MSDS Datasheet
Size	$224
	Order now
Image	(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human SUMO-conjugating enzyme UBC9 (UBE2I), partial

Product Details

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage